Ovensa Inc., a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, today announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the market.
The companies will evaluate the synergy of Celanese’s VitalDose® EVA copolymer delivery technology for drug-eluting implants and Ovensa’s TRIOZAN™ Platform for enhanced RNA, mAb and peptide-based molecule drug delivery. Ovensa and Celanese will focus on formulation development, leveraging each organization’s unique technology and expertise.